Prevention and treatment of cerebral amyloid angiopathy

Abstract

The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.

1 - 31 . (canceled) 
     
     
         32 . A method of reducing vascular amyloid in a patient, comprising
 administering an antibody that is specific for the N-terminus of Aβ in a treatment regime associated with efficacious vascular amyloid removal and reduced incidence of cerebral microhemorrhage.   
     
     
         33 . The method of  claim 32 , further comprising
 monitoring the patient for cerebral microhemorrhage by MRI.   
     
     
         34 . The method of  claim 32 , further comprising
 monitoring the patient for vascular amyloid removal by PET scan.   
     
     
         35 . The method of  claim 32 , wherein the treatment regime is a chronic treatment regime. 
     
     
         36 . The method of  claim 32 , wherein the treatment regime comprises an antibody dosage between 0.01 and 5 mg/kg body weight of the patient and administered weekly to quarterly. 
     
     
         37 - 42 . (canceled) 
     
     
         43 . The method of  claim 32 , wherein the antibody is administered intravenously or subcutaneously. 
     
     
         44 . The method of  claim 32 , wherein the antibody binds within residues 1-5 of Aβ. 
     
     
         45 . The method of  claim 32 , wherein the antibody is a humanized, human, or chimeric antibody. 
     
     
         46 . The method of  claim 45 , wherein the antibody is humanized 3D6 or humanized 12A11. 
     
     
         47 . The method of  claim 46 , wherein the humanized antibody is bapineuzumab. 
     
     
         48 - 106 . (canceled) 
     
     
         107 . A method of reducing vascular amyloid in a patient, comprising
 administering an antibody that is specific for the N-terminus of Aβ in a treatment regime associated with efficacious vascular amyloid removal, wherein the administration of the antibody restores normal vascular phenotype.   
     
     
         108 . The method of  claim 107 , wherein the treatment regime is a chronic treatment regime. 
     
     
         109 . The method of  claim 107 , wherein the treatment regime comprises an antibody dosage between 0.01 and 5 mg/kg body weight of the patient and administered weekly to quarterly. 
     
     
         110 - 114 . (canceled) 
     
     
         115 . The method of  claim 109 , wherein the dosage is administered every 13 weeks. 
     
     
         116 . The method of  claim 107 , wherein the antibody is administered intravenously or subcutaneously. 
     
     
         117 . The method of  claim 107 , wherein the antibody binds within residues 1-5 of Aβ. 
     
     
         118 . The method of  claim 107 , wherein the antibody is a humanized, human, or chimeric antibody. 
     
     
         119 . The method of  claim 118 , wherein the antibody is humanized 3D6 or humanized 12A11. 
     
     
         120 . The method of  claim 119 , wherein the humanized antibody is bapineuzumab. 
     
     
         121 - 135 . (canceled)